Cardiac Resynchronization Therapy in Heart Failure

  1. Finlay A. McAlister, MD, MSc;
  2. Natasha Wiebe, Mmath; and
  3. William Abraham, MD
  1. From University of Alberta Hospital, Edmonton, Alberta T6G 2R7, Canada; University of Alberta Campus, Edmonton, Alberta T6G 2J3, Canada; and Ohio State University, Columbus, OH 43210.
    1. Figure. CHF = congestive heart failure; CONTAK-CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; RR = relative risk.
      View larger version:
      Figure. CHF = congestive heart failure; CONTAK-CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; RR = relative risk. Heart failure hospitalizations with cardiac resynchronization therapy (CRT) versus controls.
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med February 15, 2005 vol. 142 no. 4 307-308
    1. ExcerptFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues